MedTrace Logo

Nilotinib in Parkinson's Disease

NCT03205488 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2020-07-22

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)

2 capsules taken once daily

DRUG

Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)

2 capsules taken once daily

DRUG

Placebo

2 capsules taken once daily

Sponsors & Collaborators

  • University of Rochester

    collaborator OTHER

  • University of Iowa

    collaborator OTHER

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • Northwestern University

    lead OTHER

Principal Investigators

  • Tanya Simuni, MD · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-16
Primary Completion
2019-08-26
Completion
2019-09-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03205488 on ClinicalTrials.gov